Direct-to-Tumor Drug Delivery

Maximizing impact of the most effective cancer drugs while minimizing toxicity with a first-of-its-kind approach

Traditional Cancer Drug Delivery

Inefficient delivery

0.01%

delivered systemically reaches the tumor

High toxicity

The rest spreads throughout the body, causing severe side effects
Traditional Cancer Drug Delivery

Unmet Need

The most effective cancer drugs

—the ones that could save lives—are the hardest to deliver to the tumor

Critically low survival rates

for advanced cancer patients due to a lack of effective, targeted treatments.

NaDeNo’s Nanotechnology

Direct Tumor Targeting

NaDeNo’s nanoparticles encapsulate FDA & EMA-approved drugs, protecting them during delivery and releasing them directly at the tumor site

Maximized Efficacy

Encapsulating FDA & EMA-approved drugs retain potency and time-releases them directly at the tumor for maximum impact and reduced toxicity.
NaDeNo’s Nanotechnology

Breakthrough in Cancer Care

Targets hard-to-treat cancers

NaDeNo offers pharma and biotech companies technology to overcome drug delivery challenges for their most promising drugs

97%

Tumor reduction in preclinical POC

Engineered for Stability, Safety and Superior Drug Delivery

Differentiated for Impact

Scalability

High Tumor-Specific Efficacy

  • 97% tumor reduction in preclinical ovarian cancer models compared to free drug.
  • Significantly prolongs survival rates in preclinical cancer models.
Low-Cost Manufacturing

Dual-Action Mechanism

  • Tumor specific targeting without the need of targeting ligands.
  • Delivers drugs and modifies the tumor microenvironment to enhance immune responses.
Sustainability

Scalability

  • Sustainable, one-step, proprietary manufacturing enabling cost-effective, large-scale production.
  • Uniquely stable, homogenous formulations suitable for clinical and commercial use.

Additional Unique Properties and Benefits

  • Patented technology for encapsulating hydrophobic drugs without the need for chemical modification
  • Controlled drug release profile (30% burst, 40% over 8 hours, 30% over 2-4 weeks).
  • Built with FDA-approved materials (poly(alkyl cyanoacrylate)) to minimize regulatory hurdles.

  • Especially suited for local drug delivery for direct tumor targeting
  • Enhances drug accumulation at the tumor site while reducing off-target exposure

  • Using already approved active pharmaceutical ingredients with established safety and efficacy profiles
  • Recognized by NCI (National Cancer Institute) and backed by KOL (Key Opinion Leaders).
  • Aligned with regulatory bodies for smoother clinical translation.

  • Applicable across multiple hard-to-deliver hydrophobic drugs and challenging indications.
  • Customizable surface chemistry for tailored release rates and therapeutic needs.

  • Modifies the tumor microenvironment to suppress resistance and boost treatment efficacy.

  • Robust intellectual property with granted patents covering formulation, manufacturing, and applications.
  • 4 patent families
Round NanoParticle

How it works

Effective Drug Encapsulation

NaDeno’s nanoparticles securely encapsulate hard-to-deliver drugs, protecting them during delivery.
PACAB-002 Polymer Nanoparticle
PACAB-002 Polymer Nanoparticle
Encapsulated drug
Encapsulated drug – Patented nanoformulation of Cabazitaxel*
Ready-to-use Liquid Dispersion

Ready-to-use
Liquid Dispersion

Stable, homogenous formulation for precise and efficient dosing.

Targeted Delivery

Drugs are precisely delivered to tumors in the peritoneal cavity via a catheter, achieving high tumor concentrations through receptor-independent targeting
Targeted Delivery

Even Distribution & Long Retention Time

Even Distribution

The nanoparticles provide consistent drug delivery throughout the peritoneal cavity, reaching all tumor nodules

Long Retention:

The drug remains at therapeutic levels within the target area (peritoneum) for extended periods, unlike free drug or i.v. administration, which gives minimal local effectiveness.

Even Distribution & Long Retention Time

Safe Degradation

Nanoparticles break down into non-toxic components over time, leaving no harmful residues in the body.
Safe Degradation

  • Our lead candidate, PACAB-002, is a proprietary nanoformulation of cabazitaxel encapsulated in polymeric nanoparticles

  • An undisclosed oncology pipeline is advancing in collaboration with SINTEF

  • We offer tailored nanoformulations to pharmaceutical and biotechnology companies in need of advanced solutions to overcome delivery hurdles of hydrophobic small molecule drugs

Chart

Curious to receive more detail about the Development Program and Route to Market for PACAB-002?

Lead oncology candidate

PACAB-002

  • PACAB-002 are polymeric nanoparticles encapsulating cabazitaxel

  • Cabazitaxel is highly potent and has an established safety and efficacy profile

  • Preclinical data from various mouse cancer models show:

  • long drug retention time in the peritoneal cavity
  • tumor-specific accumulation
  • even distribution throughout the peritoneal cavity
  • significantly improved treatment effect and reduced side effects compared to free drug

Management team

Management team

Annbjørg Falck

Annbjørg Falck

Chief Executive Officer
and Co-founder

Annbjørg Falck is a PharmD from the University of Oslo/University of Southern California, and she holds an MBA from the Open University in UK. She has broad experience from pharmaceutical and biotech industry, spanning from large international companies (GE Healthcare and Pfizer Norway) to pharmacy management (Boots Limited) and smaller Norwegian companies (Pronova Biopharma, Targovax, Zelluna Immunotherapy). Since 2010 she has worked in leadership roles within the field of drug development, with a main focus and enthusiasm for regulatory strategy and execution throughout the journey of bringing drugs through preclinical and clinical development to patients. Prior to co-founding NaDeNo Falck worked as an Entrepreneur in Residence for SINTEF TTO & Venture on the commercialization of SINTEF’s nanomedicine technology, resulting in the establishment of NaDeNo.

Yrr Mørch

Yrr Mørch

Chief Technology Officer
and Co-founder

Yrr Mørch is a nanomedicine specialist and one of the inventors of NaDeNo’s technology. She holds a MSc degree in chemical engineering (sivilingeniør) from The Norwegian University of Science and Technology, specializing in biotechnology. In 2008 she defended her PhD in biopolymer chemistry for which she was awarded as the top PhD thesis from Tekna in 2008. Since 2012 she has been the project leader of numerous national and international research and industry projects, has led the Nanomedicine strategic area at SINTEF and was the lead scientist of NaDeNo’s nanoformulation platform technology. Mørch is author of >40 scientific peer-reviewed publications, inventor of eight patents and has contributed as invited speaker at scientific and popular science conferences, in several newspaper articles, a podcast, and in national TV and radio interviews.

Torgeir Vaage

Torgeir Vaage

Chief Financial Officer

Torgeir Vaage holds a MSc from Norges Handelshøyskole (Norway) and a PhD from UC Berkeley in business administration. He has more than 20 years of combined experience from the financing sector and biotech with multiple CFO and CEO roles in early-stage life science companies. Vaage is the former senior equity analyst of ABG Sundal Collier/Handelsbanken and management consultant at AT Kearney.

Gudrun Trøite

Gudrun Trøite

Head of Operations

Gudrun Trøite holds a PhD in medical physics from the University of Oslo. She has 20 years of experience with drug development in small and medium size biotech companies, mainly in roles within clinical operations, regulatory affairs and quality assurance. Trøite has successfully led multi-national studies various indications and in all phases of development, including large pivotal studies leading to regulatory approval. She comes from a management team role involving development and follow-up of the company’s overall strategy and direction. She is passionate about streamlining design and management of large projects, to ensure successful conduct and reliable data to support drug development.

Partnerships

A few of our many
partners across:

Innovation & Testing

Organizations that contribute to preclinical research, early testing, and technology development.

Clinical Development

Renowned clinical institutions driving patient-focused trials to validate efficacy and safety in real-world settings.

Manufacturing & Supply Chain

Partners enabling production, scalability, and raw material sourcing.

Funding & Ecosystems

Organizations providing financial support, innovation clusters, and strategic networks

Regulatory & Intellectual Property

Experts in navigating regulatory approvals, patent protection, and compliance.

Partnership

We’re excited to announce our newest partnership with Phoenix

Insightful reads

Elesevier

What you’ll learn in this article:

  • PACA drug encapsulation improves treatment response in peritoneal metastases models.
  • Intraperitoneal injection of PACA nanoparticles provides a beneficial drug biodistribution.
  • Drug encapsulation in PACA nanoparticles improves intraperitoneal drug retention.
  • The taxane cabazitaxel is a promising chemotherapy option for peritoneal metastases.

Read the full article

Scitechnews

What you’ll learn in this article:

This article from Norwegian SciTech News will provide deeper understanding of NaDeNo’s innovative nanoparticle-based drug delivery system.

Read the full article